

Accretion Pharmaceuticals was incorporated in the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus the foundation of "Accretion Pharmaceuticals" was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Accretion Pharmaceuticals", pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of "Accretion Pharmaceuticals Limited" and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies. For details of the change in the registered office, please refer section "History and Corporate Structure of our Company" on page 204 of the Prospectus.



Please scan this OR Code to view the Prospectus)

Corporate Identity Number (CIN) of the Company is U21004GJ2023PLC146545

Regd. Office: 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213. Tel No.: +91-97148 82929; E-mail: compliance@accretionpharma.com; Website: http://www.accretionpharma.com

Contact Person: Ms. Bhavika Dhaval Makadia, Company Secretary & Compliance Officer

PROMOTERS: MR. HARSHAD NANUBHAI RATHOD, MR. VIVEK ASHOK KUMAR PATEL, MR. MAYUR POPATLAL SOJITRA AND MR. HARDIK MUKUNDBHAI PRAJAPAT

INITIAL PUBLIC OFFER OF 29,46,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF ACCRETION PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "ACCRETION" OR "THE ISSUER") AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING UP TO RS. 2,975.46 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1,47,600 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH, AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING RS. 149.08 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER TO EACH, AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING RS. 149.08 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE "MARKET MAKER TO THE "MAKER T LESS MARKET MAKER RESERVATION PORTION I.E., ISSUE OF UPTO 27,98,400 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH, AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO RS. 2,826,38 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.50% AND 25.17% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

### **RISK TO INVESTORS**

## For details refer to Section titled "Risk factors" on page 33 of the Prospectus

- Risk to Investors: Summary description of key risk factors based on materiality:
- We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.
- Our income and sales are subject to seasonal fluctuations and lower income in a peak season may have a disproportionate effect on our results of operations.
- We may be unable to respond to changes in consumer demands and market trends in a timely manner.
- Our ability to attract customers is dependent on the success and visibility of our showrooms
- The non-availability or high cost of quality gold bullion and diamonds and fluctuations in their prices may have an adverse effect on our business, results of
- Details of suitable ratios of the company and its peer group for the latest full financial year:

S. No.	Name of the company	Face Value (Rs. Per Share)	EPS (Rs.)	P/E Ratio	RoNW (%)	Net Asset value per share (Rs.)					
1	Accretion Pharmaceuticals Limited*	10	8.74   10.9		38.54%	17.09					
Peer grou	Peer group*										
2	Sakar Healthcare Limited	10	5.64	45.80	4.45%	120.65					
3	Lincoln Pharmaceuticals Limited	10	46.58	11.86	15.74%	295.98					
4	Sotac Pharmaceuticals Limited	10	5.24	22.65	11.91%	43.69					

\*Source: The Company's Financial Figures are based on restated standalone audited financial statements for the period ended on December 31, 2024 unless provided otherwise. With respect to Industry peers, all the financial information mentioned above is on a standalone basis and is sourced from the audited results of the respective companies for the year ended March 31, 2024 unless provided otherwise

\*\* Calculation done considering the floor price of Rs. 96 and cap price of RS. 101.

- P/E Ratio has been computed based on the closing market price of equity shares on NSE on April 11, 2025 divided by the Basic EPS as at March 31, 2024. Return on Net Worth (%) = net profit after tax divided by net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus/Other Equity as on March 31, 2024.
- NAV is computed as NAV is computed as the closing net worth as on March 31, 2024 divided by the outstanding number of equity shares as on March 31,
- Weighted average return on net worth for the last 3 FYs, and return on net worth for any interim period for the issuer company

(Rs.) (Rs.)

Particulars	RONW	Weight
Year ended 31st March, 2022	2.57%	1
Year ended 31st March, 2023	2.70%	2
Year ended 31st March, 2024	72.47%	3
Weighted Average	37.56%	
For the period ended December 31, 2024	38.54%	

- The figures disclosed above are based on the Restated Financial Statement of our Company. Return on Net worth has been calculated as per the following
- Return on Net Worth (%) = Restated PAT attributable to Equity Shareholders/ Net Worth X100
- Disclosures as per clause (9)(K)(4) of Part A to Schedule VI:
- The Price per share of the Company based on primary / new issue of shares (equity/convertible securities), excluding shares issued under ESOP/ESOS and issuance of bonus shares, during the 18 months preceding the date of filing of the Red Herring Prospectus/Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and No. of Equity Shares | Face value | Issue Price | (Issue price Adjusted

rice per share of the Company based on secondary sale / acquisition of shares (equity/convertible securities), where promoter / promoter group entit.	ies
r shareholder(s) selling shares through offer for sale in IPO or shareholder(s) having the right to nominate director(s) in the Board of the Company a	are
party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Red Herring Prospectus/Prospectus, where eith	
equisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital befo	ore
uch transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together o	ver
enan of rolling 30 days:	

Name of Transferee	Name of Transferor	Date of Transfer	Number of shares	Transfer price per Equity Share (in Rs.)					
Nii									

(c) Issue price and cap price being 10.1 times the weighted average cost of acquisition (WACA) based on primary/ secondary transaction(s) as disclosed in terms of clause (a) and (b) above, shall be disclosed in the following manne

,,,,,	•		
Past Transaction	WACA (in Rs.)	IPO Floor price of Rs. 96	IPO Cap price of Rs. 101
WACA of Primary Issuance	100	0.96 times	1.01 times
WACA of Secondary Transaction	Nil	NΔ	NΔ

### ANCHOR INVESTOR OFFER PRICE: RS. 101 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH ISSUE PRICE: Rs. 101 PER EQUITY SHARE OF FACE VALUE OF RS. 10 EACH THE ISSUE PRICE IS 10.1 TIMES THE FACE VALUE OF THE EQUITY SHARES. The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR")

read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of undersubscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 348 of the Prospectus.

BID/ISSUE	ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: TUESDAY, MAY 13, 2025						
•	BID/ISSUE OPENED ON: WEDNESDAY, MAY 14, 2025						
PROGRAMME:	BID/ISSUE CLOSED ON: FRIDAY, MAY 16, 2025						
PROPOSED LISTING							

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform ("NSE-EMERGE") of the National Stock Exchange of India Limited ("NSE"). Our Company has received in-principle approval from NSE for listing of the Equity Shares pursuant to its letter dated March 17, 2025. For the purposes of this Issue, NSE shall be the Designated Stock Exchange. The trading is proposed to be commenced on or about Wednesday, May 21, 2025 (Subject to receipt of listing and trading approvals from NSE)

# **SUBSCRIPTION DETAILS**

The bidding for the Anchor portion opened and closed on Tuesday, May 13, 2025. The Bid/Issue opened for public on Wednesday, May 14, 2025 and closed on Friday,

May 16, 2025 Details of Anchor Investors: The Company received a total of 2 Anchor Investor Application Forms from 2 Anchor Investors for 398,400 Equity Shares and the aggregate amount collected from applications made by such Anchor Investors was Rs. 40,238,400. A total of 211,200 Equity Shares were allocated under the Anchor Investor Portion at Rs 101 per Equity Share (including a share premium of Rs 91.00 per Equity Share) aggregating to Rs. 21,331,200/-

After the aforesaid allocation to Anchor Investors, 2,734,800 Equity Shares were available under the Issue at the higher end of the price band The Issue was subscribed to the extent of 7.3559 times (excluding Anchor Portion) as per the bid book of NSE (excluding the multiple, duplicate bids. Cancelled bids

or withdrawal bids, RC 10 and Other than RC 10 (the "Bid Book") After removing multiple and duplicate bids, Cancelled bids or withdrawal bids, RC 10 and Other than RC 10, application bid not registered and rejections cases from the "Bid Book", the Issue was subscribed 7.1698 times (excluding Anchor Allocations). The details of the applications received in the Issue from various categories are as under

Details of Application Received: (Before Technical Rejections)

Category	No. of Applications	No. of Equity Shares Applied   Equity Shares reserved as pe		
			Prospectus	Subscription**
Retail Individual Investors	10,801 ***	12,961,200***	1,222,800	10.5996
Non Institutional Investors	899	5,288,400	1,222,800	4.3248
Market Maker	1	147,600	147,600	1.0000
Qualified Institutional Bidders (excluding	4	1,719,600	141,600	12.1441
Anchor Investors)				
Anchor Investor	2	398,400	211,200	1.8864
Total	11.707	2.05.15.200	29.46.000	6.9637

\*Subscription time have been computed on the basis of the issue size as per the Prospectus

\*\*\* This excludes 30 applications for 36,000 Equity Shares from Retail Individual which were not in bid book but which were banked.

Final Demand

A summary of the final definant as per NOE as on the blu/ issue crossing Date at different blu/proces is as under.										
S. No.	Bid Price (in Rs.)	No. of Equity Shares	(%) to Total	Cumulative Total	Cumulative % To Total					
1	101	2,32,83,600	64.73%	2,32,83,600	64.73%					
2	100	1,21,200	0.34%	2,34,04,800	65.07%					
3	99	64,800	0.18%	2,34,69,600	65.25%					
4	98	61,200	0.17%	2,35,30,800	65.42%					
5	97	30,000	0.08%	2,35,60,800	65.50%					
6	96	2,80,800	0.78%	2,38,41,600	66.28%					
7	CUTOFF	1,21,29,600	33.72%	3,59,71,200	100.00%					
	Total	3,59,71,200	100.00%							

ALLOCATION: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on May 19, 2025. Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Retail Individual Investors, who have bid at the Cut-Off Price

or at the Issue Price of Rs. 101 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 10.2866 times. The total number of Equity Shares Allotted in Retail Portion is 1,222,800 Equity Shares to 1,019 successful Retail Individual Investors. The category-wise details of the

	No. of Shares applied for (Category wise)	No. of Applications Received	% to total	Total No. of Shares Applied in each	% of total	Proportionate Shares Available	Allocation p  Before Rounding off	er Applicant  After Rounding off	Allot	tio of tees to icants	Total No. of Shares Allocated/	Surplus / Deficit	
	(canogory moo)	110001100		category		7114114210	riounumg on	mountaing on			Allotted		
	1200	10482	100	12578400	100	1222800	116.65	1200	7	72	1222800	0	
<b>3</b> .	Allocation to Non I	nstitutional Inve	estors (Af	ter Technical Reie	ctions):	The Basis of Allo	tment to the No	on-Institutional	Investo	rs. who	have bid at the Iss	ue Price	

the Prospectus. Potential investors should not rely on the Prospectus filed with SEBI and the Stock Exchanges, and should instead rely on their own examination of our Company and the Issue, including the risks involved, for making any investment decision. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States solely to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) in transactions

of Rs. 101 per Equity Share, was finalized in consultation with NSE. This category has been subscribed to the extent of 4.2218 times (after rejections). The total number of Equity Shares allotted in this category is 1,222,800 Equity Shares to 672 successful Non-Institutional Investors. The category-wise details of the Basis

	No. of Shares	Number of		Total No.		Proportionate	Allocation pe	r Applicant	Ratio	n of	Total No.	
Sr. No	applied for (Category wise)	applications received	% to total	of Shares applied in each category	% to total	shares available	Before Rounding off	After Rounding off	allotte applic	es to	of shares allocated / allotted	Surplus/ Deficit
1	2400	512	59.39	1228800	23.8	291062	568.48	1200	121	256	290400	-6
2	3600	58	6.72	208800	4.04	49458	852.72	1200	41	58	49200	-2
3	4800	78	9.04	374400	7.25	88683	1136.96	1200	37	39	88800	1
4	6000	25	2.9	150000	2.9	35530	1421.2	1200	1	1	30000	-55
5	6000							1200	1	5	6000	60
6	7200	13	1.5	93600	1.81	22171	1705.46	1200	1	1	15600	-65
7	7200							1200	5	13	6000	60
8	8400	7	0.81	58800	1.13	13928	1989.71	1200	1	1	8400	-55
9	8400							1200	5	7	6000	60
10	9600	60	6.96	576000	11.15	136435	2273.91	1200	1	1	72000	-644
11	9600							1200	9	10	64800	648
12	10800	21	2.43	226800	4.39	53721	2558.14	2400	1	1	50400	-33
13	10800							1200	1	7	3600	36
14	12000	33	3.82	396000	7.67	93799	2842.39	2400	1	1	79200	-145
15	12000							1200	12	33	14400	144
16	14400	3	0.34	43200	0.83	10233	3411	2400	1	1	7200	-30
17	14400							1200	2	3	2400	24
18	15600	1	0.11	15600	0.3	3695	3695	3600	1	1	3600	-
19	16800	3	0.34	50400	0.97	11938	3979.33	3600	1	1	10800	-11
20	16800							1200	1	3	1200	12
21	18000	1	0.11	18000	0.34	4264	4264	4800	1	1	4800	5
22	19200	1	0.11	19200	0.37	4548	4548	4800	1	1	4800	2
23	21600	5	0.58	108000	2.09	25581	5116.2	4800	1	1	24000	-15
24	21600							1200	1	5	1200	12
25	22800	2	0.23	45600	0.88	10801	5400.5	4800	1	1	9600	-12
26	22800							1200	1	2	1200	12
27	24000	14	1.62	336000	6.5	79587	5684.78	4800	1	1	67200	-123
28	24000							1200	5	7	12000	120
29	25200	2	0.23	50400	0.97	11938	5969	6000	1	1	12000	
30	27600	3	0.34	82800	1.6	19612	6537.33	6000	1	1	18000	-16
31	27600							1200	1	3	1200	12
32	28800	1	0.11	28800	0.55	6822	6822	7200	1	1	7200	3
33	30000	3	0.34	90000	1.74	21318	7106	7200	1	1	21600	2
34	33600	1	0.11	33600	0.65	7959	7959	8400	1	1	8400	4
35	34800	1	0.11	34800	0.67	8243	8243	8400	1	1	8400	1
36	36000	3	0.34	108000	2.09	25581	8527	8400	1	1	25200	-3
37	40800	1	0.11	40800	0.79	9664	9664	9600	1	1	9600	
38	48000	1	0.11	48000	0.92	11370	11370	10800	1	1	10800	-5
39	49200	1	0.11	49200	0.95	11654	11654	12000	1	1	12000	3
40	50400	1	0.11	50400	0.97	11938	11938	12000	1	1	12000	
41	58800	1	0.11	58800	1.13	13928	13928	14400	1	1	14400	4
42	61200	1	0.11	61200	1.18	14496	14496	14400	1	1	14400	
43	78000	1	0.11	78000	1.51	18475	18475	18000	1	1	18000	-4
44	79200	1	0.11	79200	1.53	18760	18760	19200	1	1	19200	4
45	99600	2	0.23	199200	3.85	47184	23592	22800	1	1	45600	-15
46	99600							1200	1	2	1200	12
47	120000	1	0.11	120000	2.32	28424	28424	28800	1	1	28800	3
_	rand Total	862	100	5162400	100	1222800		_			1222800	

Note: 1 additional lot of 1200 shares have been allocated to categories 6000, 7200, 8400, 9600, 10800, 12000, 14400, 16800, 21600, 22800, 24000, 27600 & 99600 in the ratio of 1:5, 5:13, 5:7, 9:10, 1:7, 12:33, 2:3, 1:3, 1:5, 1:2, 5:7, 1:3 & 1:2 respectively

Allotment to QIBs (Excluding Anchor Investors) (after rejections): Allotment to QIBs, who have Bid at the Issue Price of Rs. 101 per Equity Share or above, has been done on a proportionate basis in consultation with the NSE. This category has been subscribed to the extent of 12.1441 times of QIB Portion. As per the SEBI ICDR Regulations, under the net QIB portion (excluding Anchor investor portion), 5% has been reserved for Mutual Funds. Since no applications were received under the Mutual Fund Category, unsubscribed portion of 7,200 Equity Shares spilled over to Other QIB category. The total number of Equity Shares Allotted in the QIB Portion is 141,600 Equity Shares which were allotted to 4 successful QIB Investors. The category-wise details of the Basis of Allotment are as under:

FPC/FII

Category Fls/Banks 20400 QIB 121200 Allotment to Anchor Investors (After Rejections): The Company, in consultation with the BRLM, have allocated 211,200 Equity Shares to 2 applications from anchor investors (including Nil Mutual Funds through Nil schemes) at the Anchor Investor Offer Price of Rs. 101 per Equity Share in accordance with the SEBI ICDF

**NBFCs** 

Category Fls/Banks Others Anchor 211200 211200

Allocation to Market Maker (After Technical Rejections): The Basis of Allotment to the Market Maker, at the issue price of Rs. 101 per Equity Share, was finalized in consultation with NSE. The category was subscribed by 1,0000 times. The total number of shares allotted in this category 147,600 Equity Shares to 1 successful

No. of Shares Proportionate Allocation per Applicant | Ration of applications Shares applic of shares applied for total Before allottees to (Category received in each available allocated applicants wise) category allotted 147600 147600 147600 147600 100 147600 100 147600

**Grand Total** 100 147600 100 147600 147600 The Board of Directors of the Company at its meeting held on May 19, 2025 has taken on record the Basis of Allocation of Equity Shares approved by the Designated Stock Exchange and has authorized the corporate action for the transfer of the Equity Shares to various successful applicants

The refund / allotment intimation will be dispatched to the address of the Applicants as registered with the depositories on or about May 20, 2025. Further, the instructions to Self-Certified Syndicate Banks for unblocking the amount will be processed on or prior to May 20, 2025. In case the same is not received within ten days, investors may contact Registrar at the address given below

The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on NSE within three working days from the date of the closure of the Issue. Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated May 19, 2025 ("Prospectus")

## CORRIGENDUM TO THE PROSPECTUS DATED MAY 19, 2025 - NOTICE TO INVESTORS (THE "CORRIGENDUM")

This is with reference to the Prospectus filed by our Company with the Registrar of Companies, Ahmedabad ("RoC"). In Point No 6(a) and 6(b) of "Table- I -Summary Statement Holding of Specified Securities", corresponding to the sub-head "Shareholding Pattern of our Company" on Page 89 of the Prospectus, Investors are requested to note that out of total shareholding of 81,70,000 equity shares of Promoter and Promoter Group, representing 100% of the share capital of the Company as on the date of the Prospectus, were under lock-in as on the date of the Prospectus. Further, In Point No 6(a) and 6(b) of "Table II - Statement Showing shareholding pattern of the Promoter and Promoter Group", on Page 90 of the Prospectus, Investors are requested to note that the Shareholding of the constituents of the Promoter Group, i.e. - Mayurbhai Popatlal Sojitra - 19,66,500 Equity Shares (being 100% of total shares held), Vivek Ashok Kumar Patel - 19,66,500 Equity Shares (being 100% of total shares held), Harshad Nanubhai Rathod - 19,66,500 Equity Shares (being 100% of total shares held). Hardik Mukundbhai Prajapati - 19.66.500 Equity Shares (being 100% of total shares held). Ankita Vivek Patel - 76.000 Equity Shares (being 100% of total shares held), Rathod Pooja Harshad - 76,000 Equity Shares (being 100% of total shares held), Shweta Sojitra - 76,000 Equity Shares (being 100% of total shares held), and Vaishaki Hardik

### Prajapati - 76,000 Equity Shares (being 100% of total shares held), is locked in as on the date of the Prospectus **INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, Kfin Technologies Limited at www.kfintech.com.

Place: Ahmedabad

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

# KFIN TECHNOLOGIES LIMITED

CIN: L72400TG2017PLC117649

Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana Tel: +91 40 6716 2222; Toll Free No.: 1800 309 4001;

Email Id: apl.ipo@kfintech.com; Investor Grievance Email Id: einward.ris@kfintech.com; Website: www.kfintech.com

Contact Person: Mr. M Murali Krishna; SEBI Registration No.: INR000000221

For **Accretion Pharmaceuticals Limited** 

Vivek Ashok Kumar Patel

Managing Director DIN: 09130357

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS

PROSPECTS OF ACCRETION PHARMACEUTICALS LIMITED. ACCRETION PHARMACEUTICALS LIMITED has filed the Prospectus with RoC and the Stock Exchanges on May 19, 2025. The Prospectus is expected to be available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges i.e. NSE at www.nseindia.com, respectively, the website of the Company at http://www.

accretionpharma.com and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Jawa Capital Services Private Limited at www.jawacapital.in. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" beginning on page 33 of exempt from or not subject to the registration requirements of the U.S. Securities Act and (b) outside the United States in "offshore transactions" as defined in and in reliance on Regulation S of the U.S. Securities Act and the applicable laws of each jurisdiction where such offers and sales are made.